For instance, the KEYNOTE-028 phase Ib study necessitated PD-L1 expression exceeding 1% on tumor or stromal cells, per measurement by the 22C3 assay, for advanced-stage solid tumors patients who received Pembrolizumab (41). Here, CD274 is linked to neoplasm.